{"id":"W2898490299","doi":"10.1093/annonc/mdy424.065","title":"IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"ca_institutions":"William Osler Health System","funders":"KU Leuven; Genentech; AstraZeneca; Celgene; Novartis Pharma; Astellas Pharma; Clovis Oncology; Taiho Pharmaceutical; Pfizer","keywords":"Medicine; Internal medicine; Atezolizumab; Pemetrexed; Oncology; Population; Carboplatin; Docetaxel; Progression-free survival; Adverse effect; Paclitaxel; Clinical endpoint; Chemotherapy; Randomized controlled trial; Cancer; Cisplatin; Nivolumab; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004678981,0.001517858,0.002371674,0.0006353711,0.0003477228,0.001473216,0.001245888,0.001516548,0.007238559],"category_scores_gemma":[0.00361667,0.000689464,0.004643633,0.0006384097,0.001244799,0.00136883,0.0009947082,0.0043856,0.0009002987],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00114501,"about_ca_system_score_gemma":0.001641833,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006383705,"about_ca_topic_score_gemma":0.001920869,"domain_scores_codex":[0.9980718,0.001171733,0.00009662872,0.000225544,0.0001994485,0.0002348316],"domain_scores_gemma":[0.9977385,0.0007807545,0.0005441098,0.0002426781,0.00009238956,0.0006014725],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9645687,0.003758651,0.002384265,0.0004837954,0.002536117,0.00004764743,0.00005159488,0.001104275,0.004635281,0.0001521773,0.001336316,0.01894107],"study_design_scores_gemma":[0.8307057,0.1442928,0.01544551,0.00004982663,0.004479421,0.0001500527,0.00003852264,0.001191711,0.001355483,0.0003552967,0.001884516,0.00005110849],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9866838,0.002435468,0.0009543099,0.0005616793,0.000126152,0.001559931,0.005218391,0.000150389,0.002309806],"genre_scores_gemma":[0.9843255,0.001256512,0.001326342,0.000794352,0.0002421229,0.001432404,0.008790516,0.00007139087,0.001760958],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007238559,"threshold_uncertainty_score":0.02474511,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03699190091645593,"score_gpt":0.4389857752545097,"score_spread":0.4019938743380537,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}